Bristol-Myers Squibb Aktie

Bristol-Myers Squibb für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 850501 / ISIN: US1101221083

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.06.2015 21:00:00

Moody's: Immuno-oncology drugs credit positive for drug makers; competition high

New York, June 15, 2015 -- Immuno-oncology drugs are credit positive for key players in the pharmaceutical industry, including Bristol-Myers Squibb, Merck & Co., Inc., Roche Holdings and AstraZeneca, Moody's Investors Service says in a new report. Bristol-Myers Squibb is currently the leader in the development and commercialization of the new drugs, but competitors are not far behind.

Vollständigen Artikel bei Moodys lesen